Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IDM01 is a proprietary botanical extract derived from *Ilex paraguariensis* (Yerba Mate), developed by IDM Food Solutions. It is standardized to contain high concentrations of bioactive compounds, specifically 20% caffeine and 10% chlorogenic acids. The extract is primarily investigated for its potential to alleviate general fatigue and enhance cognitive performance, including mental focus and alertness, in healthy, recreationally active adults. Its mechanism of action is largely attributed to the antagonism of adenosine receptors by caffeine, which inhibits the sleep-promoting effects of adenosine and reduces the perception of effort during physical or mental tasks. Additionally, the chlorogenic acid content provides antioxidant support. Clinical Research Australia has managed randomized, double-blind, placebo-controlled clinical trials to assess the safety and efficacy of IDM01 capsules in improving stamina and cognitive function.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on IDM01.